ABS’s buyout of Cureline’s excellence to bolster biopharma drug discovery

Introduction

ABS Bio, since its establishment in 1990, has delivered the best-in-class critical scientific relevant services involving tissue processing, cell culture, human biospecimens, biostorage and cell line engineering. This contributed a lot to biotech and pharmaceutical companies building and elevating the standard of research and drug discovery. The company is well concentrated on signing the complicated research activities to prove its potential in the healthcare market and achieve the set goals of ease, quality and gain trust across their client-centric current and future approaches.

Whereas, Cureline Inc., which came into force in 2003, is a biorepository and a worldwide Contract Research Organisation (CRO) known for its commendable delivery of high-quality human biospecimens (HBS) and relevant research services. The services are for diagnostic and biopharmaceutical companies.

Announcement

ABS Bio Inc. acquired South San Francisco-based Cureline, Inc.'s excellence. According to the acquisition deal between the two companies, the expansion is the clear and main motive, whereas the complementary service will be served to 300 clinical noted sites globally. Both entities will serve the fastest and widest range of services to the diagnostics' valuable clients and biopharma discovery.

This valuable deal is entitled to bolstering footprint of the company's efforts and advancements. Furthermore, the acquisition terms have not yet been revealed. This business deal will bring more profit and recognition to the entity's door.

Statements from healthcare leaders

CEO of ABS Bio, Ehab Alramahy, said, “We are sticking to our intention of extending the potential of ABS Bio, for which we find Cureline an ideal one to fit in our smart strategy. Cureline’s services, location and team are perfect for our mission and a push to our existing strengths. We’re thrilled to introduce them to our operation and team, further awaiting their service offering to our joint clients.”

“By joining hands, we will have a close look and clarity into clients’ needs and be able to deliver quick results. This will help us to leverage the operational quality of the research we stand by.”

CEO and Founder of Cureline, PhD, Olga Potapova, said, “We are thrilled to walk a journey with ABS Bio. Their seriousness for science and client-centric focus make them a perfect company that we were looking for our research partners and customers. We believe that together we’ll deliver excellent services that will satisfy our existing and future clients.”